Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Raymond James from $24.00 to $12.00. They now have an "outperform" rating on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Piper Sandler from $30.00 to $23.00. They now have an "overweight" rating on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Needham & Company LLC from $23.00 to $15.00. They now have a "buy" rating on the stock.